European fund buys into PharmaZen biotech
Biotechnology company PharmaZen said it has sold a 13.8 percent stake in the company to ADM Capital Europe's agri-tech focused Cibus Fund for $14 million.The Christchurch-based firm, which develops nutraceutical ingredients for dietary supplements aimed at the human and pet-food market, issued 35 million new shares to Cibus, at an issue price of 40 cents each. That's a 13 percent discount on its volume-weighted average price of the past 12-months. The USX-listed stock has traded in a range from 21 cents to 60 cents over that period...
Login to read
Try free for 10 days
Trustworthy, balanced journalism every day from our growing team of New Zealand business reporters and commentators, plus more in our weekend magazine section, The Life.
- Instant News Alerts based on keywords you choose or journalists you follow
- Our Daily Digest of all stories at 6am, midday or 6pm
- A custom library of your saved stories
- An industry-leading search engine
- Try for 10 days without paying and if you’re not convinced cancel with just two clicks.
Support quality New Zealand journalism by subscribing today.
Find out moreUse the information you’ve already given Google to create your subscription.
Not convinced yet?
Subscribe to our Daily News Update free newsletter.
Loading...